AFFY warns that unless O returns to market in the near future it must go BK. The SA article, disclosing 22 suspected O deaths, means that Takeda's task of convincing the FDA that O is safe will be many times more difficult and time consuming than merely dealing with the 3 O anaphylaxis deaths cited in the O recall notice. The test is not whether O ever returns to market, but will O return to market soon enough to save AFFY shareholders.
If one reads the AFFY longs, they are all excited about the potential for a short squeeze, especially with the Oct 17 options expiration and the 31,500 open interest in the $2 calls. That is a very different reason to buy and hold AFFY vis a vis any fundamentals about AFFY's financial prospects.
I believe most AFFY longs know AFFY is a dead duck in the long term and that the "big payout" is just not in the cards.